Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Nov 4;138(18):1646-1648.
doi: 10.1182/blood.2021013087.

Epigenetic plasticity of erythroid progenitors

Marjorie Brand  1
Affiliations
Editorial

Epigenetic plasticity of erythroid progenitors

Marjorie Brand. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
In committed adult EPs, differentiation toward the myeloid lineage is actively repressed by the chromatin-modifying enzyme LSD1. If LSD1 is depleted or inactivated pharmacologically, the cells convert to GMPs characterized by increased expression of the myeloid-specifying gene Pu.1. CMP, common myeloid progenitor; MEP, megakaryocyte-erythroid progenitor. See Figure 5F in the article by Yu et al that begins on page 1691.
See this image and copyright information in PMC

Comment on

References

    1. Yu L, Myers G, Ku CJ, et al. . An erythroid-to myeloid-cell fate conversion is elicited by LSD1 inactivation. Blood. 2021;138(18):1691-1704. - PMC - PubMed
    1. Olivieri NF, Weatherall DJ.. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet. 1998;138(18):1655-1658. - PubMed
    1. Sankaran VG, Menne TF, Xu J, et al. . Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science. 2008;138(18):1839-1842. - PubMed
    1. Esrick EB, Lehmann LE, Biffi A, et al. . Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021;138(18):205-215. - PMC - PubMed
    1. Frangoul H, Altshuler D, Cappellini MD, et al. . CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia. N Engl J Med. 2021;138(18):252-260. - PubMed